Abstract
Background: Venous thromboembolism (VTE), characterized by thrombus formation in veins, ranks as the third most prevalent vascular disease globally after myocardial infarction (MI) and stroke. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are common clinical manifestations of VTE, with potentially fatal consequences. In this study, the mean daily warfarin dose using VKORC1 (-1639 G>A) rs9923231 genotyping will be established in order to categorize warfarin treatment into high, moderate, and low-dose groups within the South Indian population. Methods and Materials: A cohort of 192 patients was enrolled, and genotyping was conducted using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Results: In our study sample, the A allele frequency was 23.9%, and the AA genotype frequency was 12.5%. The mean daily doses required by AA homozygous (1.54 ± 1.05 mg/day) and GA heterozygous (2.93 ± 2.03 mg/day) genotype carriers were considerably lower to attain the optimal international normalized ratio (INR) than those of GG genotype carriers (4.07 ± 1.75 mg/day), with a p-value of 0.866. Conclusion: Our findings strongly advocate for incorporating VKORC1 polymorphism analysis in South Indian patients with DVT to guide the initial warfarin dosage genetically.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
